
The Skyrizi approval pairs an interleukin-23 antibody with an on-body injector for 720 mg subcutaneous induction in adults, per phase 3 AFFIRM data.
Curtis (Curt) Rosebraugh, MD, has been appointed as the new director of the US Food and Drug Administration’s (FDA) Office of Drug Evaluation II.
Curtis (Curt) Rosebraugh, MD, has been appointed as the new director of the US Food and Drug Administration’s (FDA) Office of Drug Evaluation II. In 2000, Rosebraugh joined the FDA as a medical officer in the Division of Pulmonary and Allergy Drugs Products. From 2003–2005, he served as the deputy director of the Office of Nonprescription Products and was acting director of the Division of Nonprescription Clinical Evaluation in that office. In 2005, he became deputy director of the Office of Drug Evaluation II and became acting director in September 2007.






